# EDGAR Filing Document

**Accession Number:** 0001157601
**File Stem:** 0001628280-25-032358
**Filing Date:** 2025-6
**Character Count:** 7074
**Document Hash:** 34ef78099792245b60817a7f9b2067b2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-25-032358.hdr.sgml**: 20250620

**ACCESSION NUMBER**: 0001628280-25-032358

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250620

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250620

**DATE AS OF CHANGE**: 20250620

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MADRIGAL PHARMACEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0001157601
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-33277
- **FILM NUMBER:** 251061277

**BUSINESS ADDRESS:**
- **STREET 1:** 200 BARR HARBOR DRIVE, SUITE 400
- **CITY:** WEST CONSHOHOCKEN
- **STATE:** PA
- **ZIP:** 19428
- **BUSINESS PHONE:** 404-380-9263

**MAIL ADDRESS:**
- **STREET 1:** 200 BARR HARBOR DRIVE, SUITE 400
- **CITY:** WEST CONSHOHOCKEN
- **STATE:** PA
- **ZIP:** 19428

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SYNTA PHARMACEUTICALS CORP
- **DATE OF NAME CHANGE:** 20010815

?xml version='1.0' encoding='ASCII'? mdgl-20250620

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

____________________

**FORM 8-K**

____________________

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 20, 2025**

____________________

**MADRIGAL PHARMACEUTICALS, INC.**

**(Exact name of registrant as specified in its charter)**

____________________

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-33277** | **04-3508648** |
| **(State or other jurisdiction**<br>**of incorporation)** | **(Commission**<br>**File Number)** | **(IRS Employer**<br>**Identification No.)** |

---

---

| | |
|:---|:---|
| **Four Tower Bridge**<br>**200 Barr Harbor Drive, Suite 200**<br>**West Conshohocken, Pennsylvania** | **19428** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**(267) 824-2827**

**Registrant's telephone number, including area code**

**(Former name or former address, if changed since last report)**

____________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange**<br>**on which registered** |
| Common Stock, $0.0001 Par Value Per Share | MDGL | The NASDAQ Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company □

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

------

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On June 20, 2025, Madrigal Pharmaceuticals, Inc. (the "Company") held its 2025 Annual Meeting of Stockholders (the "Annual Meeting"). As of April 24, 2025, the record date for the Annual Meeting, 22,203,282 shares of the Company's common stock were issued and outstanding, of which 20,427,421 shares of the Company's common stock were present in person or represented by proxy and entitled to vote at the Annual Meeting, constituting a quorum. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below.

1. The Company's stockholders re-elected the four persons listed below as Class III directors, each to serve until the Company's 2028 annual meeting of stockholders or until his or her successor is duly elected and qualified. The voting results were as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **<u>For</u>** | **<u>Withheld</u>** | **<u>Broker Non-Votes</u>** |
| Julian C. Baker | 17,144,833 | 1,806,070 | 1,476,517 |
| Raymond Cheong, Ph.D., M.D. | 18,218,687 | 732,216 | 1,476,517 |
| Jacqualyn A. Fouse, Ph.D. | 18,845,616 | 105,287 | 1,476,517 |
| Richard S. Levy, M.D. | 17,734,255 | 1,216,648 | 1,476,517 |

---

2. The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. The voting results were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **<u>For</u>** | **<u>Against</u>** | **<u>Abstentions</u>** | **<u>Broker Non-Votes</u>** |
| 20,230,193 | 179,959 | 17,269 | 0 |

---

3. The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers. The voting results were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **<u>For</u>** | **<u>Against</u>** | **<u>Abstentions</u>** | **<u>Broker Non-Votes</u>** |
| 18,720,175 | 208,911 | 21,817 | 1,476,517 |

---

4. The Company's stockholders approved, on a non-binding, advisory basis, a frequency of every "One Year" for future advisory stockholder votes on the compensation of the Company's named executive officers. The voting results were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **<u>One Year</u>** | **<u>Two Years</u>** | **<u>Three Years</u>** | **<u>Abstentions</u>** | **<u>Broker Non-Votes</u>** |
| 18,863,579 | 7,011 | 64,052 | 16,261 | 1,476,517 |

---

After considering the results of the non-binding, advisory vote, the Board of Directors of the Company has determined that the Company will hold a non-binding, advisory vote on the compensation of its named executive officers every year until the next required advisory vote on the frequency of holding the advisory vote on named executive officer compensation.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **MADRIGAL PHARMACEUTICALS, INC.** | **MADRIGAL PHARMACEUTICALS, INC.** |
| | By: | /s/ Mardi Dier |
| | | Name: Mardi Dier |
| | | Title: Executive Vice President and Chief Financial Officer |
| Date: June 20, 2025 |  |  |

---